Syed F. Ali
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Researcher
Also affiliated: Boston University (2013); Bluefield State College (2022); Meharry Medical College (1998–2007); Cedars-Sinai Medical Center (2022); Brigham and Women's Hospital (2015); MedStar Washington Hospital Center (2022); United States Department of Health and Human Services (2016); Beth Israel Deaconess Medical Center (2014); United States Food and Drug Administration (1989–2022); Westchester Medical Center (2023–2024); National Institute on Drug Abuse (1998); St. George's University (2018); Harvard University (2013–2015); North Park University (2022); FMC (United States) (1992–2007); Madurai Medical College (2022); Jinan University (2012); University of San Diego (2019); University of California, Los Angeles (2013–2014); University of Calgary (2013–2015); Iowa State University (2006); New York Medical College (2023); Chevron (Netherlands) (2002–2006); Dalian Medical University (2004); University of Saint Joseph (2024); Princeton University (1995); University of California, Irvine (1995); Krishna University (2022–2025); University of Utah (2018); The University of Agriculture, Peshawar (2004); Augusta University (2018); Royal Devon & Exeter NHS Foundation Trust (2025); Biochemical Society (2009); Diabetes Australia (2022); Ronald Reagan UCLA Medical Center (2015); Centre Hospitalier Universitaire Vaudois (2014); Geological Survey of Sweden (2007); LMU Klinikum (2018); Bowie State University (2022); University of California San Diego (2004–2020); Shaheed Zulfiqar Ali Bhutto Institute of Science and Technology (2025); Z.V.M.Unani Medical College & Hospital (2025); Massachusetts General Hospital (1998–2017); Clinical Research Institute (2013–2015); National Institute of Environmental Health Sciences (1983–1984); Assistance Publique – Hôpitaux de Paris (2014); Zimmer Biomet (United States) (2003); Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques (2011); Chevron (United States) (1996–2006); Aurora Medical Center (2022–2023); Duke Medical Center (2014); Kokilaben Dhirubhai Ambani Hospital (2014); Irvine University (1995); Instituto Nacional de Neurología y Neurocirugía (2001); National Institute for Research and Development of Isotopic and Molecular Technologies (2010); Food and Drug Administration (2015); Institute of Molecular Biology and Biophysics (1991); Duke University Hospital (2014); Phoenixville Hospital (2022); National Research Council Canada (1986); Arkansas Department of Agriculture (2017); Jefferson Hospital for Neuroscience (2008); Neurochlore (France) (2009); University of Regensburg (2018); Drexel University (2022); University of Pennsylvania (2013); Florida Agricultural and Mechanical University (1997); Michigan State University (2013–2015); Texas A&M University (1995)
Faculty Researcher
Upstream record may be merged OpenAlex, the source of these figures, lists 72 institutions in 17 countries for this author record — a pattern that usually means it combines several researchers with similar names. The totals above may include work by other people.
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Syed F. Ali's research program focuses on understanding the impact of various agents and conditions on biological systems, with a significant emphasis on the central nervous system. His work investigates neurobiological responses to traumatic brain injury, examining molecular and cellular changes such as neurogenesis, inflammation, and cell death. Ali also studies the effects of substance abuse, including methamphetamine and novel psychoactive substances, on emotional behavior and glial cell activation in animal models.
Beyond neurobiology, Ali's research extends to cardiovascular health and disease mechanisms, as evidenced by his work on coronary artery dissection and myocarditis. He has also contributed to the medical literature through case reports detailing adverse drug reactions and rare medical conditions, such as serotonin syndrome and eosinophilic granulomatosis with polyangiitis.
With a substantial publication record, including 589 total publications and over 20,000 citations, Ali is recognized as a highly cited researcher. His collaborations include work with researchers at the University of Arkansas at Fayetteville. He maintains an active lab website to disseminate his research findings.
Metrics
- h-index: 75
- Publications: 587
- Citations: 20,972
Selected Publications
-
Retraction notice to “On the in vivo early toxic properties of Aβ25–35 peptide in the rat hippocampus: Involvement of the Receptor-for-Advanced Glycation-End-Products and changes in gene expression” [Neurotoxicology and Teratology 33 (2011) 288–296] (2025)
-
Retraction notice to “On the early toxic effect of quinolinic acid: Involvement of RAGE” [Neurosci. Lett. 474(2) (2010) 74–78] (2024)
-
The Endocannabinoid System in the Central Nervous System: Emphasis on the Role of the Mitochondrial Cannabinoid Receptor 1 (mtCB1R) (2022)
-
Functional Analysis of the Cortical Transcriptome and Proteome Reveal Neurogenesis, Inflammation, and Cell Death after Repeated Traumatic Brain Injury <i>In vivo</i> (2022)
-
Autophagy and protein aggregation as a mechanism of dopaminergic degeneration in a primary human dopaminergic neuronal model (2022)
-
Blood–Brain Barrier Breakdown and Astrocyte Reactivity Evident in the Absence of Behavioral Changes after Repeated Traumatic Brain Injury (2021)
-
The Endocannabinoid System in the Central Nervous System: Emphasis on the Role of the Mitochondrial Cannabinoid Receptor 1 (mtCB1R) (2021)
-
Acute MDPV Binge Paradigm on Mice Emotional Behavior and Glial Signature (2021)
-
Neurotoxicity of thallium: Old issues and new developments (2021)
-
Amyloid Beta 25–35 induces blood-brain barrier disruption in vitro (2019)
-
Iron oxide nanoparticles induce cytokine secretion in a complement-dependent manner in a human whole blood model (2017)
Collaboration Network
Top Collaborators
- The Endocannabinoid System in the Central Nervous System: Emphasis on the Role of the Mitochondrial Cannabinoid Receptor 1 (mtCB1R)
- Neurotoxicity of thallium: Old issues and new developments
- The Endocannabinoid System in the Central Nervous System: Emphasis on the Role of the Mitochondrial Cannabinoid Receptor 1 (mtCB1R)
- Retraction notice to “On the early toxic effect of quinolinic acid: Involvement of RAGE” [Neurosci. Lett. 474(2) (2010) 74–78]
- Retraction notice to “On the in vivo early toxic properties of Aβ25–35 peptide in the rat hippocampus: Involvement of the Receptor-for-Advanced Glycation-End-Products and changes in gene expression” [Neurotoxicology and Teratology 33 (2011) 288–296]
- Autophagy and protein aggregation as a mechanism of dopaminergic degeneration in a primary human dopaminergic neuronal model
- Retraction notice to “On the early toxic effect of quinolinic acid: Involvement of RAGE” [Neurosci. Lett. 474(2) (2010) 74–78]
- Retraction notice to “On the in vivo early toxic properties of Aβ25–35 peptide in the rat hippocampus: Involvement of the Receptor-for-Advanced Glycation-End-Products and changes in gene expression” [Neurotoxicology and Teratology 33 (2011) 288–296]
- The Endocannabinoid System in the Central Nervous System: Emphasis on the Role of the Mitochondrial Cannabinoid Receptor 1 (mtCB1R)
- The Endocannabinoid System in the Central Nervous System: Emphasis on the Role of the Mitochondrial Cannabinoid Receptor 1 (mtCB1R)
- The Endocannabinoid System in the Central Nervous System: Emphasis on the Role of the Mitochondrial Cannabinoid Receptor 1 (mtCB1R)
- The Endocannabinoid System in the Central Nervous System: Emphasis on the Role of the Mitochondrial Cannabinoid Receptor 1 (mtCB1R)
- The Endocannabinoid System in the Central Nervous System: Emphasis on the Role of the Mitochondrial Cannabinoid Receptor 1 (mtCB1R)
- The Endocannabinoid System in the Central Nervous System: Emphasis on the Role of the Mitochondrial Cannabinoid Receptor 1 (mtCB1R)
- The Endocannabinoid System in the Central Nervous System: Emphasis on the Role of the Mitochondrial Cannabinoid Receptor 1 (mtCB1R)
- The Endocannabinoid System in the Central Nervous System: Emphasis on the Role of the Mitochondrial Cannabinoid Receptor 1 (mtCB1R)
- The Endocannabinoid System in the Central Nervous System: Emphasis on the Role of the Mitochondrial Cannabinoid Receptor 1 (mtCB1R)
- The Endocannabinoid System in the Central Nervous System: Emphasis on the Role of the Mitochondrial Cannabinoid Receptor 1 (mtCB1R)
- The Endocannabinoid System in the Central Nervous System: Emphasis on the Role of the Mitochondrial Cannabinoid Receptor 1 (mtCB1R)
- The Endocannabinoid System in the Central Nervous System: Emphasis on the Role of the Mitochondrial Cannabinoid Receptor 1 (mtCB1R)
- Blood–Brain Barrier Breakdown and Astrocyte Reactivity Evident in the Absence of Behavioral Changes after Repeated Traumatic Brain Injury
- Functional Analysis of the Cortical Transcriptome and Proteome Reveal Neurogenesis, Inflammation, and Cell Death after Repeated Traumatic Brain Injury <i>In vivo</i>
- Blood–Brain Barrier Breakdown and Astrocyte Reactivity Evident in the Absence of Behavioral Changes after Repeated Traumatic Brain Injury
- Functional Analysis of the Cortical Transcriptome and Proteome Reveal Neurogenesis, Inflammation, and Cell Death after Repeated Traumatic Brain Injury <i>In vivo</i>
- Blood–Brain Barrier Breakdown and Astrocyte Reactivity Evident in the Absence of Behavioral Changes after Repeated Traumatic Brain Injury
- Functional Analysis of the Cortical Transcriptome and Proteome Reveal Neurogenesis, Inflammation, and Cell Death after Repeated Traumatic Brain Injury <i>In vivo</i>
- Retraction notice to “On the early toxic effect of quinolinic acid: Involvement of RAGE” [Neurosci. Lett. 474(2) (2010) 74–78]
- Retraction notice to “On the in vivo early toxic properties of Aβ25–35 peptide in the rat hippocampus: Involvement of the Receptor-for-Advanced Glycation-End-Products and changes in gene expression” [Neurotoxicology and Teratology 33 (2011) 288–296]
- Retraction notice to “On the early toxic effect of quinolinic acid: Involvement of RAGE” [Neurosci. Lett. 474(2) (2010) 74–78]
- Retraction notice to “On the in vivo early toxic properties of Aβ25–35 peptide in the rat hippocampus: Involvement of the Receptor-for-Advanced Glycation-End-Products and changes in gene expression” [Neurotoxicology and Teratology 33 (2011) 288–296]
- Retraction notice to “On the early toxic effect of quinolinic acid: Involvement of RAGE” [Neurosci. Lett. 474(2) (2010) 74–78]
- Retraction notice to “On the in vivo early toxic properties of Aβ25–35 peptide in the rat hippocampus: Involvement of the Receptor-for-Advanced Glycation-End-Products and changes in gene expression” [Neurotoxicology and Teratology 33 (2011) 288–296]
- Retraction notice to “On the early toxic effect of quinolinic acid: Involvement of RAGE” [Neurosci. Lett. 474(2) (2010) 74–78]
- Retraction notice to “On the in vivo early toxic properties of Aβ25–35 peptide in the rat hippocampus: Involvement of the Receptor-for-Advanced Glycation-End-Products and changes in gene expression” [Neurotoxicology and Teratology 33 (2011) 288–296]
Similar Researchers
Based on overlapping research topics